NWBOOTCPharmaceutical PreparationsFiscal year ends December 31

NORTHWEST BIOTHERAPEUTICS INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$0.16−0.00 (-0.88%)

Close on Oct 19, 2026

Market cap: $254.79M
P/E (TTM): –
Dividend yield: –

NORTHWEST BIOTHERAPEUTICS INC income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31	FY 2007 2007-12-31	FY 2006 2006-12-31
Revenue	1.38	1.38	1.93	1.68	1.01	1.29	2.41	0.41	0.34	0.62	1.74	1.45	0.81	0.77	0.01	0.01	–	–	–	–
Cost of Revenue	–	–	–	–	–	–	–	–	–	–	–	–	0	0	0	0	–	–	–	–
Gross Profit	–	–	–	–	–	–	–	–	–	–	–	–	0.81	0.77	0.01	0.01	–	–	–	–
Research & Development	29	35	28	36	20	34	14	18	34	60	103	86	44	29	13	9.90	–	–	–	–
General & Administrative	33	33	30	33	33	54	16	23	12	11	18	17	12	16	13	5.46	–	–	–	–
Operating Income	-60	-67	-56	-67	-53	-87	-28	-41	-55	-79	-126	-101	-55	-44	-27	-15	–	–	–	–
Interest Expense	8.70	7.77	5.24	6.07	5.01	8.54	2.98	9.87	5.55	3.82	4.15	1.00	0.84	13	7.65	7.88	–	–	–	–
Other Non-Operating Income	-0.79	-17	-7.09	-38	232	-443	7.17	5.69	-18	–	–	–	–	–	–	–	–	–	–	–
Merger & Restructuring Charges	–	–	–	–	–	–	–	–	–	0	-0.05	0	0	–	–	–	–	–	–	–
Asset Impairment Charges	0	0	0	0	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	–	–	–	–	–	–	0	3.28	0	–	–	–	–	–	–	–	–	–	–	–
Legal Settlements	–	–	–	–	–	–	-0.25	–	–	–	–	–	–	–	–	–	–	–	–	–
Pretax Income	-61	-84	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Income Tax Expense	-0.54	0	0	0	0	0	0	0	0	0	0	0	0	0	–	–	–	–	–	–
Net Income incl. Noncontrolling Interests	-60	-84	-63	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Net Income	-60	-84	-63	-105	179	-530	-21	-36	-73	-80	-115	-136	-66	-67	-33	-27	-27	-22	-21	-1.40
Preferred Dividends	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-1.25	–
Net Income to Common	-61	-85	-64	-105	179	-530	-21	-54	-74	-86	-115	–	-66	-67	-33	-27	–	–	–	–
EPS (Basic)(per share)	-0.04	-0.07	-0.06	-0.10	0.21	-0.73	-0.04	-0.12	-0.31	-0.77	-1.48	-2.29	-2.00	-5.72	-5.58	-6,560.00	–	–	–	–
EPS (Diluted)(per share)	-0.04	-0.07	-0.06	-0.10	-0.06	-0.73	-0.04	-0.12	-0.31	-0.77	-1.48	-2.29	-2.00	-5.72	-5.58	–	–	–	–	–
Shares Outstanding (Basic, Weighted)(shares)	1,457	1,242	1.12	1.02	0.87	0.73	0.56	440	243	111	78	59	33	0.01	0.01	0.00	–	–	–	–
Shares Outstanding (Diluted, Weighted)(shares)	1,457	1,242	1.12	1.02	1.01	0.73	0.56	440	243	111	78	59	33	0.01	0.01	0.00	–	–	–	–
EBITDA	-58	-65	-54	-66	-52	-87	-28	-40	-54	-79	-126	-101	-55	-44	-27	-15	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -2316.1%
Net margin: -1736.4%
Return on equity, FY2025: 77.7%

Financial strength

Current ratio: 0.04
Debt to equity: -0.27
Debt to assets: 16.1%
Cash to current liabilities: 0.8%

Valuation

P/E ratio: –
Price to sales: 117.25
Price to book: –
Dividend yield: –